Decyphering cancer with preclinical solutions

Bruker’s in vivo innovative imaging technologies and reagents enable scientists and researchers to effeciently and reliably analyze and characterize tumor burden, disease progression, angiogenesis and metastases over the course of time – while utilizing only a limited number of animals.

Thus, our customers can create comprehensive models of biologically relevant disease patterns and biomarker expressions. Longitudinal in vivo imaging provides key insights into disease development, therapeutic response and toxicology. We offer a wide portfolio of instruments, instrument families and reagents for non-invasive imaging for oncology applications – today playing an important role in drug development.

Learn more